Cardiac Failure Review最新文献_第10页

Viscoelastic Haemostatic Assays in Cardiovascular Critical Care. 心血管危重症的粘弹性止血试验。

Cardiac Failure Review Pub Date : 2021-02-19 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.22

Aniket S Rali, Ahmed M Salem, Melat Gebre, Taylor M Garies, Siva Taduru, Arthur W Bracey

{"title":"Viscoelastic Haemostatic Assays in Cardiovascular Critical Care.","authors":"Aniket S Rali, Ahmed M Salem, Melat Gebre, Taylor M Garies, Siva Taduru, Arthur W Bracey","doi":"10.15420/cfr.2020.22","DOIUrl":"https://doi.org/10.15420/cfr.2020.22","url":null,"abstract":"The initiation and management of anticoagulation is a fundamental practice for a wide variety of indications in cardiovascular critical care, including the management of patients with acute MI, stroke prevention in patients with AF or mechanical valves, as well as the prevention of device thrombosis and thromboembolic events with the use of mechanical circulatory support and ventricular assist devices. The frequent use of antiplatelet and anticoagulation therapy, in addition to the presence of concomitant conditions that may lead to a propensity to bleed, such as renal and liver dysfunction, present unique challenges. The use of viscoelastic haemostatic assays provides an additional tool allowing clinicians to strike a delicate balance of attaining adequate anticoagulation while minimising the risk of bleeding complications. In this review, the authors discuss the role that viscoelastic haemostatic assay plays in cardiac populations (including cardiac surgery, heart transplantation, extracorporeal membrane oxygenation, acute coronary syndrome and left ventricular assist devices), and identify areas in need of further study.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e01"},"PeriodicalIF":0.0,"publicationDate":"2021-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/ec/cfr-07-e01.PMC7919676.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25467261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes? 新发心力衰竭和急性失代偿慢性心力衰竭的临床特征：它们是导致不同结果的独特表型吗？

IF 4.2

Cardiac Failure Review Pub Date : 2021-02-19 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.20

Wilson Matthew Raffaello, Joshua Henrina, Ian Huang, Michael Anthonius Lim, Leonardo Paskah Suciadi, Bambang Budi Siswanto, Raymond Pranata

引用次数: 0

Pulmonary Embolism and Heart Failure: A Reappraisal. 肺栓塞和心力衰竭:重新评估。

Cardiac Failure Review Pub Date : 2021-02-18 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.26

Mattia Arrigo, Lars Christian Huber

引用次数: 12

Acute Heart Failure in Coronavirus Disease 2019 and the Management of Comedications. 2019冠状病毒病急性心力衰竭及药物管理

Cardiac Failure Review Pub Date : 2020-11-23 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.24

Chia Siang Kow, Syed Shahzad Hasan

引用次数: 0

Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice. 钠-葡萄糖共转运蛋白2抑制剂在心力衰竭中的应用:最新数据和实践意义。

Cardiac Failure Review Pub Date : 2020-11-13 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.23

Giuseppe Rosano, David Quek, Felipe Martínez

{"title":"Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice.","authors":"Giuseppe Rosano, David Quek, Felipe Martínez","doi":"10.15420/cfr.2020.23","DOIUrl":"https://doi.org/10.15420/cfr.2020.23","url":null,"abstract":"Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium.glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to prevent primary and secondary hospitalisation due to heart failure and cardiovascular death in these patients. Data from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) and Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced) have demonstrated the positive clinical impact of SGLT2 inhibition in patients with heart failure with reduced ejection fraction both with and without T2D. These data have led to the approval of dapagliflozin for the treatment of patients with heart failure with reduced ejection fraction, irrespective of T2D status. This article reviews the latest data reported from the DAPA-HF and EMPEROR-Reduced trials and their clinical implications for the treatment of patients with heart failure.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e31"},"PeriodicalIF":0.0,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/87/cfr-06-e31.PMC7689869.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38688925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Corrigendum to: Pulmonary Hypertension in Heart Failure Patients. 心力衰竭患者肺动脉高压的勘误表。

Cardiac Failure Review Pub Date : 2020-10-23 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.1.1

Sriram D Rao, Srinath Adusumalli, Jeremy A Mazurek

引用次数: 0

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction. 运动训练对保留射血分数心力衰竭患者心功能的影响。

Cardiac Failure Review Pub Date : 2020-10-16 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.17

Hidekatsu Fukuta

引用次数: 6

Determinants of Functional Capacity and Quality of Life After Implantation of a Durable Left Ventricular Assist Device. 植入耐用左心室辅助装置后功能能力和生活质量的决定因素。

Cardiac Failure Review Pub Date : 2020-10-16 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.15

Kiran K Mirza, Finn Gustafsson

{"title":"Determinants of Functional Capacity and Quality of Life After Implantation of a Durable Left Ventricular Assist Device.","authors":"Kiran K Mirza, Finn Gustafsson","doi":"10.15420/cfr.2020.15","DOIUrl":"https://doi.org/10.15420/cfr.2020.15","url":null,"abstract":"Continuous-flow left ventricular assist devices (LVAD) are increasingly used as destination therapy in patients with end-stage heart failure and, with recent improvements in pump design, adverse event rates are decreasing. Implanted patients experience improved survival, quality of life (QoL) and functional capacity (FC). However, improvement in FC and QoL after implantation is not unequivocal, and this has implications for patient selection and preimplantation discussions with patients and relatives. This article identifies preimplantation predictors of lack of improvement in FC and QoL after continuous-flow LVAD implantation and discusses potential mechanisms, allowing for the identification of potential factors that can be modified. In particular, the pathophysiology behind insufficient improvement in peak oxygen uptake is discussed. Data are included from 40 studies, resulting in analysis of >700 exercise tests. Mean peak oxygen uptake was 13.4 ml/kg/min (equivalent to 48% of predicted value; 259 days after implantation, range 31-1,017 days) and mean 6-minute walk test distance was 370 m (182 days after implantation, range 43-543 days). Finally, the interplay between improvement in FC and QoL is discussed.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e29"},"PeriodicalIF":0.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/55/cfr-06-e29.PMC7592460.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38561090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition. 中程或恢复射血分数心力衰竭:过渡的不同决定因素。

Cardiac Failure Review Pub Date : 2020-10-16 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.13

Davide Margonato, Simone Mazzetti, Renata De Maria, Marco Gorini, Massimo Iacoviello, Aldo P Maggioni, Andrea Mortara

{"title":"Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition.","authors":"Davide Margonato, Simone Mazzetti, Renata De Maria, Marco Gorini, Massimo Iacoviello, Aldo P Maggioni, Andrea Mortara","doi":"10.15420/cfr.2020.13","DOIUrl":"https://doi.org/10.15420/cfr.2020.13","url":null,"abstract":"The recent definition of an intermediate clinical phenotype of heart failure (HF) based on an ejection fraction (EF) of between 40% and 49%, namely HF with mid-range EF (HFmrEF), has fuelled investigations into the clinical profile and prognosis of this patient group. HFmrEF shares common clinical features with other HF phenotypes, such as a high prevalence of ischaemic aetiology, as in HF with reduced EF (HFrEF), or hypertension and diabetes, as in HF with preserved EF (HFpEF), and benefits from the cornerstone drugs indicated for HFrEF. Among the HF phenotypes, HFmrEF is characterised by the highest rate of transition to either recovery or worsening of the severe systolic dysfunction profile that is the target of disease-modifying therapies, with opposite prognostic implications. This article focuses on the epidemiology, clinical characteristics and therapeutic approaches for HFmrEF, and discusses the major determinants of transition to HFpEF or HFrEF.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e28"},"PeriodicalIF":0.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/6c/cfr-06-e28.PMC7592465.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38561089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Congestion and Diuretic Resistance in Acute or Worsening Heart Failure. 急性或加重心力衰竭的充血和利尿剂抵抗。

Cardiac Failure Review Pub Date : 2020-09-28 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.18

Ingibjörg Kristjánsdóttir, Tonje Thorvaldsen, Lars H Lund

引用次数: 15